JP2019536740A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536740A5 JP2019536740A5 JP2019515905A JP2019515905A JP2019536740A5 JP 2019536740 A5 JP2019536740 A5 JP 2019536740A5 JP 2019515905 A JP2019515905 A JP 2019515905A JP 2019515905 A JP2019515905 A JP 2019515905A JP 2019536740 A5 JP2019536740 A5 JP 2019536740A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- amino acid
- binding
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC[C@]1CC[C@](CN(C(C[C@@]2SCCC(N(C)[C@@](C)C(O[C@@](CC(N(*)c(cc(CC(C)=CC=C[C@]([C@@](C3)(N4)O)OC)cc5OC)c5Cl)=O)[C@]5(C)O[C@]5C[C@]3OC4=O)=O)=O)=O)C2=O)CC1 Chemical compound CC[C@]1CC[C@](CN(C(C[C@@]2SCCC(N(C)[C@@](C)C(O[C@@](CC(N(*)c(cc(CC(C)=CC=C[C@]([C@@](C3)(N4)O)OC)cc5OC)c5Cl)=O)[C@]5(C)O[C@]5C[C@]3OC4=O)=O)=O)=O)C2=O)CC1 0.000 description 1
- PLNMJXBWNJMINP-UHFFFAOYSA-N O=C(CC1)N(CC2CCCCC2)C1=O Chemical compound O=C(CC1)N(CC2CCCCC2)C1=O PLNMJXBWNJMINP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662399249P | 2016-09-23 | 2016-09-23 | |
| US62/399,249 | 2016-09-23 | ||
| US201762558711P | 2017-09-14 | 2017-09-14 | |
| US62/558,711 | 2017-09-14 | ||
| PCT/US2017/053113 WO2018067331A1 (en) | 2016-09-23 | 2017-09-22 | Bi specific anti-muc16-cd3 antibodies and nti-muc16 drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536740A JP2019536740A (ja) | 2019-12-19 |
| JP2019536740A5 true JP2019536740A5 (enExample) | 2020-11-05 |
| JP7066691B2 JP7066691B2 (ja) | 2022-05-13 |
Family
ID=60083442
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515905A Active JP7066691B2 (ja) | 2016-09-23 | 2017-09-22 | 二重特異性抗ｍｕｃ１６－ｃｄ３抗体および抗ｍｕｃ１６薬物複合体 |
| JP2019515904A Active JP7066690B2 (ja) | 2016-09-23 | 2017-09-22 | 抗ｍｕｃ１６（ムチン１６）抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515904A Active JP7066690B2 (ja) | 2016-09-23 | 2017-09-22 | 抗ｍｕｃ１６（ムチン１６）抗体 |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US10941208B2 (enExample) |
| EP (3) | EP3515946B1 (enExample) |
| JP (2) | JP7066691B2 (enExample) |
| KR (2) | KR102531251B1 (enExample) |
| CN (2) | CN110214026B (enExample) |
| AU (2) | AU2017331363B2 (enExample) |
| BR (2) | BR112019005670A2 (enExample) |
| CA (4) | CA3287248A1 (enExample) |
| CL (4) | CL2019000712A1 (enExample) |
| CO (1) | CO2019003967A2 (enExample) |
| CY (1) | CY1125577T1 (enExample) |
| DK (2) | DK3515487T5 (enExample) |
| ES (2) | ES2925563T3 (enExample) |
| FI (1) | FI3515487T3 (enExample) |
| HR (2) | HRP20221202T1 (enExample) |
| HU (2) | HUE059761T2 (enExample) |
| IL (2) | IL265309B2 (enExample) |
| LT (2) | LT3515487T (enExample) |
| MD (1) | MD3515487T2 (enExample) |
| MX (2) | MX2019003322A (enExample) |
| MY (2) | MY200230A (enExample) |
| PH (2) | PH12019500550A1 (enExample) |
| PL (2) | PL3515946T3 (enExample) |
| PT (2) | PT3515946T (enExample) |
| RS (2) | RS63660B1 (enExample) |
| SI (2) | SI3515946T1 (enExample) |
| SM (2) | SMT202200359T1 (enExample) |
| WO (2) | WO2018067331A1 (enExample) |
| ZA (2) | ZA201901557B (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| DK3277725T3 (da) | 2015-03-30 | 2021-01-11 | Regeneron Pharma | Konstante tungkædeområder med reduceret binding til FC-gammareceptorer |
| EA039859B1 (ru) | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| MY195059A (en) | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| US11583593B2 (en) | 2016-01-14 | 2023-02-21 | Synthis Therapeutics, Inc. | Antibody-ALK5 inhibitor conjugates and their uses |
| AR107582A1 (es) | 2016-02-03 | 2018-05-16 | Amgen Res Munich Gmbh | Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t |
| KR102531251B1 (ko) | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| RS67792B1 (sr) | 2016-12-01 | 2026-03-31 | Regeneron Pharma | Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje |
| BR112019016336A2 (pt) * | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| RU2747095C2 (ru) * | 2018-05-11 | 2021-04-26 | Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) | Мономолекулярный химерный т-клеточный рецептор к раковому антигену са125 |
| CN108659131B (zh) * | 2018-05-28 | 2021-09-14 | 长春力太生物技术有限公司 | 一种抗ceacam-5的单域抗体及其应用 |
| CN119143875A (zh) | 2018-06-21 | 2024-12-17 | 瑞泽恩制药公司 | 双特异性抗psma x抗cd28抗体及其用途 |
| TW202504917A (zh) | 2018-06-21 | 2025-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法 |
| TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| LT4324851T (lt) | 2018-07-19 | 2025-10-10 | Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas | |
| MX2021002165A (es) | 2018-08-23 | 2021-07-16 | Regeneron Pharma | Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos. |
| ES3009025T3 (en) | 2018-08-31 | 2025-03-25 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies |
| CA3116717A1 (en) | 2018-10-31 | 2020-05-07 | Regeneron Pharmaceuticals, Inc. | Method and system of identifying and quantifying a protein |
| JP7627216B2 (ja) * | 2018-11-16 | 2025-02-05 | メモリアル スローン ケタリング キャンサー センター | ムチン－１６に対する抗体およびそれを使用する方法 |
| US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
| WO2020132024A1 (en) * | 2018-12-19 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
| KR20210104836A (ko) | 2018-12-19 | 2021-08-25 | 리제너론 파아마슈티컬스, 인크. | 이중 특이적 항-cd28 x 항-cd22 항체 및 그의 용도 |
| EA202192422A1 (ru) | 2019-03-05 | 2021-12-09 | Ридженерон Фармасьютикалз, Инк. | Человеческий сывороточный альбумин в составах |
| EP3941941A1 (en) | 2019-03-22 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Egfr x cd28 multispecific antibodies |
| US12617866B2 (en) * | 2019-05-08 | 2026-05-05 | Memorial Sloan Kettering Cancer Center | Humanized antibodies to mucin-16 and methods of use thereof |
| WO2020256721A1 (en) * | 2019-06-19 | 2020-12-24 | Synthis, Llc | Antib0dy-alk5 inhibitor conjugates and their uses |
| JP7743314B2 (ja) * | 2019-06-21 | 2025-09-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
| CN114401988A (zh) | 2019-07-09 | 2022-04-26 | 国家生物技术研究所公司 | 具有降低的免疫原性的抗体 |
| MX2022001942A (es) * | 2019-08-15 | 2022-07-27 | Regeneron Pharma | Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. |
| TW202108631A (zh) * | 2019-08-21 | 2021-03-01 | 大陸商和鉑醫藥（上海）有限責任公司 | 一種抗ｃｄ４７抗原結合蛋白及其應用 |
| EP4025605A1 (en) * | 2019-09-06 | 2022-07-13 | Symphogen A/S | Anti-cd73 antibodies |
| CN114340684B (zh) | 2019-09-16 | 2025-09-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
| US11814428B2 (en) | 2019-09-19 | 2023-11-14 | Regeneron Pharmaceuticals, Inc. | Anti-PTCRA antibody-drug conjugates and uses thereof |
| WO2021081232A1 (en) | 2019-10-23 | 2021-04-29 | Cue Biopharma, Inc. | Modified cytotoxic t cells and methods of use thereof |
| IL309560B2 (en) | 2019-12-06 | 2025-05-01 | Regeneron Pharma | Anti-VEGF protein preparations and methods for their production |
| JP7693672B2 (ja) * | 2019-12-06 | 2025-06-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| EP4267722A1 (en) * | 2020-12-22 | 2023-11-01 | Amgen Inc. | Diffusion gradient assay for anti-cd3-containing molecules |
| CA3202891A1 (en) | 2021-01-28 | 2022-08-04 | Kara Olson | Compositions and methods for treating cytokine release syndrome |
| AU2022221297A1 (en) * | 2021-02-09 | 2023-08-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies targeting the spike protein of coronaviruses |
| EP4308160A4 (en) * | 2021-03-18 | 2025-07-02 | Memorial Sloan Kettering Cancer Center | METHODS OF TREATING GYNECOLOGICAL CANCER USING COMBINATION THERAPY WITH MULTISPECIFIC ANTI-MUC16 X CD3 ANTIBODIES AND VEGF INHIBITORS |
| TW202304507A (zh) * | 2021-04-02 | 2023-02-01 | 美商再生元醫藥公司 | 含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物 |
| CN117320700A (zh) * | 2021-04-02 | 2023-12-29 | 瑞泽恩制药公司 | 含有抗muc16 x抗cd3双特异性抗体的稳定制剂 |
| EP4355778A1 (en) | 2021-06-17 | 2024-04-24 | Boehringer Ingelheim International GmbH | Novel tri-specific binding molecules |
| MX2024006187A (es) | 2021-11-24 | 2024-08-14 | Regeneron Pharma | Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4. |
| MX2024008055A (es) | 2022-01-07 | 2024-09-06 | Regeneron Pharma | Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1. |
| US20250092135A1 (en) * | 2022-01-10 | 2025-03-20 | Nanjing Leads Biolabs Co., Ltd. | Antibody and use thereof |
| WO2023133358A2 (en) * | 2022-01-10 | 2023-07-13 | 2Seventy Bio, Inc. | Muc16 chimeric antigen receptors |
| IL315405A (en) | 2022-03-17 | 2024-11-01 | Regeneron Pharma | Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| JP2025529310A (ja) * | 2022-09-06 | 2025-09-04 | ティージェイ バイオファーマ （シャンハイ） カンパニー， リミテッド | 多特異性構築物およびその使用 |
| WO2024123698A1 (en) | 2022-12-08 | 2024-06-13 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
| AU2024223918A1 (en) | 2023-02-17 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
| JP2026508624A (ja) | 2023-03-13 | 2026-03-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性抗ｃｄ２２×抗ｃｄ２８分子でがんを治療する方法 |
| CN121399157A (zh) | 2023-06-12 | 2026-01-23 | 美国安进公司 | 淋巴毒素β受体激动剂结合蛋白 |
| JP2026524012A (ja) | 2023-07-10 | 2026-07-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性ｐｄ－ｌ１×４－１ｂｂ抗体およびそれらの使用方法 |
| JP2026524011A (ja) | 2023-07-10 | 2026-07-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 二重特異性ｐｄ－ｌ１×ｃｄ２８抗体およびそれらの使用方法 |
| WO2025036848A1 (en) | 2023-08-11 | 2025-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Anti-muc16 antibodies and uses thereof |
| CN117024596B (zh) * | 2023-08-18 | 2024-02-27 | 镜像绮点(上海)细胞技术有限公司 | 肿瘤原代细胞特异性标记与活体成像 |
| EP4791777A1 (en) | 2023-10-09 | 2026-08-19 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer with a combination of a taaxcd3 bispecific antibody and a targeted immunocytokine |
| CN119978126A (zh) * | 2023-11-10 | 2025-05-13 | 深圳市菲鹏生物治疗股份有限公司 | 抗muc16抗体、靶向muc16的嵌合抗原受体及其应用 |
| AR134368A1 (es) * | 2023-11-17 | 2026-01-07 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-muc16 y usos de los mismos |
| TW202539732A (zh) | 2023-11-29 | 2025-10-16 | 美商再生元醫藥公司 | 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法 |
| TW202542187A (zh) | 2023-12-12 | 2025-11-01 | 美商再生元醫藥公司 | 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法 |
| TW202617776A (zh) | 2024-07-10 | 2026-05-01 | 美商再生元醫藥公司 | 治療ｓｍａｒｃｂ１缺陷型癌症之方法 |
| WO2026037330A1 (en) * | 2024-08-14 | 2026-02-19 | Leads Biolabs Inc. | Antibodies binding to cd3 and uses thereof |
| WO2026050255A2 (en) | 2024-08-27 | 2026-03-05 | Regeneron Pharmaceuticals, Inc. | Anti-slc3a2-apis antigen-binding proteins and methods of use thereof |
| WO2026096576A1 (en) | 2024-10-30 | 2026-05-07 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules that bind psma and 4-1bb and methods of use thereof |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| AU2002254615A1 (en) | 2001-04-17 | 2002-10-28 | The Board Of Trustees Of The University Of Arkansas | Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions |
| DE50105971D1 (de) | 2001-12-04 | 2005-05-25 | Brahms Ag | Verfahren zur Diagnose von Sepsis unter Bestimmung von CA 125 |
| DK1551876T3 (da) | 2002-10-16 | 2011-06-14 | Purdue Pharma Lp | Antistoffer, der binder til celle-associerede ca 125/0722P og fremgangsmåder til anvendelse deraf |
| AU2004242845B2 (en) | 2003-05-31 | 2011-06-02 | Amgen Research (Munich) Gmbh | Human-anti-human CD3 binding molecules |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| PE20090245A1 (es) | 2007-05-08 | 2009-03-17 | Genentech Inc | Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos |
| US7985557B2 (en) | 2007-05-23 | 2011-07-26 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| US8187801B2 (en) | 2008-04-24 | 2012-05-29 | Wisconsin Alumni Research Foundation | Methods and kits to detect and monitor ovarian cancer and preeclampsia |
| UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| ES2560807T3 (es) | 2008-07-21 | 2016-02-22 | Polytherics Limited | Nuevos reactivos y procedimiento de conjugación de moléculas biológicas |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| DK2889624T3 (en) | 2009-08-10 | 2018-12-10 | Ucl Business Plc | Reversible covalent bonding of functional molecules |
| SG183149A1 (en) | 2010-02-08 | 2012-09-27 | Regeneron Pharma | Common light chain mouse |
| CA2793753C (en) | 2010-03-26 | 2018-06-05 | Memorial Sloan-Kettering Cancer Center | Antibodies to muc16 and methods of use thereof |
| PT2528625E (pt) | 2010-04-15 | 2013-10-17 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| WO2012070029A1 (en) * | 2010-11-26 | 2012-05-31 | University Of The Witwatersrand, Johannesburg | A pharmaceutical composition |
| DK2714685T3 (en) | 2011-05-27 | 2017-01-09 | Ambrx Inc | FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| AU2012322934B2 (en) | 2011-10-14 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepines |
| JP6166728B2 (ja) | 2011-10-14 | 2017-07-19 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体 |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| BR112014013526A8 (pt) | 2011-12-05 | 2017-06-13 | Igenica Biotherapeutics Inc | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP3964237B1 (en) | 2013-03-15 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Biologically active molecules, conjugates thereof, and therapeutic uses |
| AU2014311361B2 (en) | 2013-08-26 | 2018-11-29 | Regeneron Pharmaceuticals, Inc. | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| HUE050159T2 (hu) * | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| TWI754319B (zh) * | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| EA201790719A1 (ru) * | 2014-09-26 | 2017-07-31 | Макродженикс, Инк. | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения |
| KR102618312B1 (ko) | 2015-03-17 | 2023-12-28 | 메모리얼 슬로안 케터링 캔서 센터 | 항muc16 항체 및 그의 용도 |
| CA2978340C (en) | 2015-03-27 | 2024-05-28 | Regeneron Pharmaceuticals, Inc. | Maytansinoid derivatives, conjugates thereof, and methods of use |
| MY195059A (en) | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| KR102531251B1 (ko) | 2016-09-23 | 2023-05-15 | 리제너론 파아마슈티컬스, 인크. | 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체 |
| JP7743314B2 (ja) * | 2019-06-21 | 2025-09-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｍｕｃ１６およびｃｄ３に結合する二重特異性抗原結合分子の４－１ｂｂ共刺激と組み合わせての使用 |
| TW202304507A (zh) * | 2021-04-02 | 2023-02-01 | 美商再生元醫藥公司 | 含有抗ｍｕｃ１６ｘ抗ｃｄ３雙特異性抗體之穩定調配物 |
| MX2024006187A (es) * | 2021-11-24 | 2024-08-14 | Regeneron Pharma | Métodos para tratar el cáncer con anticuerpos biespecíficos anti-cd3 x muc16 y anticuerpos anti-ctla-4. |
| MX2024008055A (es) * | 2022-01-07 | 2024-09-06 | Regeneron Pharma | Métodos para tratar el cáncer ovarico recurrente con anticuerpos biespecificos anti-muc16 x anti-cd3 solos o en combinación con anticuerpos anti-pd-1. |
-
2017
- 2017-09-22 KR KR1020197010783A patent/KR102531251B1/ko active Active
- 2017-09-22 CN CN201780067123.9A patent/CN110214026B/zh active Active
- 2017-09-22 PL PL17787989.7T patent/PL3515946T3/pl unknown
- 2017-09-22 DK DK17784089.9T patent/DK3515487T5/da active
- 2017-09-22 KR KR1020197011419A patent/KR102418667B1/ko active Active
- 2017-09-22 HU HUE17787989A patent/HUE059761T2/hu unknown
- 2017-09-22 IL IL265309A patent/IL265309B2/en unknown
- 2017-09-22 MY MYPI2019001374A patent/MY200230A/en unknown
- 2017-09-22 PT PT177879897T patent/PT3515946T/pt unknown
- 2017-09-22 EP EP17787989.7A patent/EP3515946B1/en active Active
- 2017-09-22 SI SI201731189T patent/SI3515946T1/sl unknown
- 2017-09-22 AU AU2017331363A patent/AU2017331363B2/en active Active
- 2017-09-22 FI FIEP17784089.9T patent/FI3515487T3/fi active
- 2017-09-22 HR HRP20221202TT patent/HRP20221202T1/hr unknown
- 2017-09-22 IL IL265369A patent/IL265369B2/en unknown
- 2017-09-22 ES ES17787989T patent/ES2925563T3/es active Active
- 2017-09-22 RS RS20220906A patent/RS63660B1/sr unknown
- 2017-09-22 MY MYPI2019001357A patent/MY194596A/en unknown
- 2017-09-22 SM SM20220359T patent/SMT202200359T1/it unknown
- 2017-09-22 CA CA3287248A patent/CA3287248A1/en active Pending
- 2017-09-22 CA CA3037738A patent/CA3037738A1/en active Pending
- 2017-09-22 WO PCT/US2017/053113 patent/WO2018067331A1/en not_active Ceased
- 2017-09-22 LT LTEPPCT/US2017/053113T patent/LT3515487T/lt unknown
- 2017-09-22 MX MX2019003322A patent/MX2019003322A/es unknown
- 2017-09-22 US US15/713,578 patent/US10941208B2/en active Active
- 2017-09-22 MD MDE20190826T patent/MD3515487T2/ro unknown
- 2017-09-22 JP JP2019515905A patent/JP7066691B2/ja active Active
- 2017-09-22 RS RS20230945A patent/RS64691B1/sr unknown
- 2017-09-22 DK DK17787989.7T patent/DK3515946T5/da active
- 2017-09-22 CN CN201780071820.1A patent/CN110036032B/zh active Active
- 2017-09-22 BR BR112019005670-0A patent/BR112019005670A2/pt active Search and Examination
- 2017-09-22 SI SI201731387T patent/SI3515487T1/sl unknown
- 2017-09-22 ES ES17784089T patent/ES2952735T3/es active Active
- 2017-09-22 CA CA3315142A patent/CA3315142A1/en active Pending
- 2017-09-22 HU HUE17784089A patent/HUE063020T2/hu unknown
- 2017-09-22 HR HRP20231281TT patent/HRP20231281T1/hr unknown
- 2017-09-22 AU AU2017339711A patent/AU2017339711B2/en active Active
- 2017-09-22 EP EP23182446.7A patent/EP4273172A3/en active Pending
- 2017-09-22 CA CA3037536A patent/CA3037536C/en active Active
- 2017-09-22 PL PL17784089.9T patent/PL3515487T3/pl unknown
- 2017-09-22 BR BR112019005697-1A patent/BR112019005697A2/pt active Search and Examination
- 2017-09-22 PT PT177840899T patent/PT3515487T/pt unknown
- 2017-09-22 WO PCT/US2017/053114 patent/WO2018058003A1/en not_active Ceased
- 2017-09-22 SM SM20230308T patent/SMT202300308T1/it unknown
- 2017-09-22 JP JP2019515904A patent/JP7066690B2/ja active Active
- 2017-09-22 LT LTEPPCT/US2017/053114T patent/LT3515946T/lt unknown
- 2017-09-22 MX MX2019003326A patent/MX2019003326A/es unknown
- 2017-09-22 EP EP17784089.9A patent/EP3515487B1/en active Active
- 2017-09-22 US US15/713,574 patent/US10738130B2/en active Active
-
2019
- 2019-03-13 ZA ZA2019/01557A patent/ZA201901557B/en unknown
- 2019-03-14 PH PH12019500550A patent/PH12019500550A1/en unknown
- 2019-03-14 ZA ZA2019/01591A patent/ZA201901591B/en unknown
- 2019-03-19 PH PH12019500604A patent/PH12019500604A1/en unknown
- 2019-03-19 CL CL2019000712A patent/CL2019000712A1/es unknown
- 2019-03-20 CL CL2019000726A patent/CL2019000726A1/es unknown
- 2019-04-22 CO CONC2019/0003967A patent/CO2019003967A2/es unknown
-
2020
- 2020-06-26 US US16/913,154 patent/US11485793B2/en active Active
-
2021
- 2021-10-08 CL CL2021002645A patent/CL2021002645A1/es unknown
-
2022
- 2022-09-26 US US17/953,114 patent/US12570764B2/en active Active
- 2022-09-27 CY CY20221100635T patent/CY1125577T1/el unknown
-
2023
- 2023-09-08 CL CL2023002690A patent/CL2023002690A1/es unknown
-
2026
- 2026-02-06 US US19/532,633 patent/US20260234286A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532056A5 (enExample) | ||
| JP2025111463A5 (enExample) | ||
| JP6800853B2 (ja) | 抗ｃ１０ｏｒｆ５４抗体およびその使用 | |
| JP6010241B2 (ja) | Ｄｌｌ３モジュレーター及び使用方法 | |
| JP2019146572A5 (enExample) | ||
| JP2024544520A5 (enExample) | ||
| US20190218304A1 (en) | Potentiating the effect of atp release | |
| JP2017535257A5 (enExample) | ||
| EP3880712A1 (en) | MONOCLONAL ANTIBODIES AGAINST IgV DOMAIN OF B7-H3 AND USES THEREOF | |
| TW202330036A (zh) | 抗體-藥物結合物之製造方法 | |
| JP2017535246A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| KR20160097336A (ko) | 신규 항-ｄｐｅｐ3 항체 및 이의 사용 방법 | |
| KR20160037130A (ko) | 신규한 항체 접합체 및 이의 용도 | |
| JP2021523100A5 (enExample) | ||
| JP2017510559A5 (enExample) | ||
| JP2012522513A5 (enExample) | ||
| IL302818A (en) | Treatment of cancer | |
| RU2015110632A (ru) | Молекулы, связывающиеся с 4-1вв | |
| KR20170010764A (ko) | 신규한 항-ｒｎｆ43 항체 및 사용 방법 | |
| KR20170045351A (ko) | 신규한 항-mfi2 항체 및 사용 방법 | |
| JP7264831B2 (ja) | 抗ｇｌｏｂｏ ｈ抗体を含有する抗体－薬物コンジュゲートおよびその使用 | |
| JP2014515600A5 (enExample) | ||
| JP2022523360A5 (enExample) | ||
| JP2019525727A (ja) | 新規の抗ｔｎｆｒｓｆ２１抗体及び使用方法 |